Cymbalta for generalised anxiety disorder

The licence for Cymbalta (duloxetine) has been extended to include use in the treatment of generalised anxiety disorder (GAD).

The recommended starting dose in patients with GAD is 30mg once daily, taken with or without food. In patients with insufficient response the dose should be increased to 60mg, the usual maintenance dose in most patients.

In patients with co-morbid major depressive episodes, the starting and maintenance dose is 60mg once daily.

Doses up to 120mg daily have been shown to be efficacious and have been evaluated for safety in clinical trials; escalation up to 90mg or 120mg may be considered for patients with insufficient response to 60mg.

After consolidation of the response, continue treatment for several months to avoid relapse.

Further information: Lilly
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases